Sitnez Biocare Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-07-2024
- Paid Up Capital ₹ 0.10 M
as on 25-07-2024
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.30 M
as on 25-07-2024
- Revenue -6.62%
(FY 2023)
- Profit -16.96%
(FY 2023)
- Ebitda 1.25%
(FY 2023)
- Net Worth 19.49%
(FY 2023)
- Total Assets -19.43%
(FY 2023)
About Sitnez Biocare
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.30 M.
Goldi Kumari and Ravi Ranjan serve as directors at the Company.
- CIN/LLPIN
U24232CH2011PTC033335
- Company No.
033335
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Nov 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sitnez Biocare Private Limited offer?
Sitnez Biocare Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Kidney Drugs, Pharma & Bioanalytical Services, PCD Pharma Franchise, Digestive System Drugs & Medicines, Digestive Drugs, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Ayurvedic,Herbal Products & Medicine, Ayurvedic Herbal Syrups & Tonics.
Who are the key members and board of directors at Sitnez Biocare?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Goldi Kumari  | Director | 07-Jan-2014 | Current |
| Ravi Ranjan | Director | 02-Nov-2011 | Current |
Financial Performance of Sitnez Biocare.
Sitnez Biocare Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6.62% decrease. The company also saw a substantial fall in profitability, with a 16.96% decrease in profit. The company's net worth Soared by an impressive increase of 19.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sitnez Biocare?
In 2023, Sitnez Biocare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 25 Feb 2019 | ₹7.30 M | Open |
How Many Employees Work at Sitnez Biocare?
Unlock and access historical data on people associated with Sitnez Biocare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sitnez Biocare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sitnez Biocare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
